# Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.

- **DOI:** [10.1038/s41467-026-74744-z](https://doi.org/10.1038/s41467-026-74744-z)
- **Rating:** Sound (3.1 out of 5)
- **Verdict:** Multimodal evidence positions ImP as an Alzheimer’s disease modifier, but single-instrument causal inference and uncorrected microbiome analyses overstate the human case.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41467-026-74744-z

## Key claims

1. In a cohort of 1196 cognitively unimpaired adults, higher plasma ImP levels were associated with lower preclinical cognitive scores and biomarkers of ADRD, both cross-sectionally and longitudinally.
   - Support: Tentative
   - Type: Primary finding
   - Basis: longitudinal grouping does not establish exposure precedence and includes extrapolated trajectory interpretations
   - Location: Abstract; Results, Figs. 1–2
2. Genome-wide integrative analysis revealed a locus on chromosome 12 associated with both plasma ImP levels and AD risk in humans, supporting a host genetic contribution to ImP regulation and a causal role of this metabolite in AD.
   - Support: Tentative
   - Type: Secondary
   - Basis: one genetic instrument with multiple eQTL targets cannot exclude horizontal pleiotropy
   - Location: Abstract; Results, Fig. 4
3. In mice, chronic ImP administration exacerbated AD-like pathology.
   - Support: Supported
   - Type: Secondary
   - Basis: two male mouse models show convergent pathology, but small clustered samples and protocol discrepancies limit certainty
   - Location: Abstract; Results, Fig. 5
4. ImP impaired brain endothelial barrier and promoted tau hyperphosphorylation in primary neurons, an effect blocked by glycogen synthase kinase-3β inhibition.
   - Support: Supported
   - Type: Secondary
   - Basis: direct cell and mouse assays support direction, though small samples and uncorrected neuronal comparisons limit specificity
   - Location: Abstract; Results, Fig. 6
5. Fecal metagenomic analysis linked putative ImP producers to ADRD phenotypes.
   - Support: Tentative
   - Type: Secondary
   - Basis: many taxa–biomarker tests were uncorrected and only one urdA-positive taxon tracked plasma ImP
   - Location: Abstract; Results, Fig. 3

## Strengths

- **Integrated evidence across biological scales** The study links a 1,196-person observational cohort to metagenomics, human genetics, two transgenic mouse models, and endothelial and neuronal assays. This creates a coherent program for testing the ImP hypothesis across complementary systems.
  - Dimension: contribution
  - Location: Abstract; Results, Figs. 1–6
- **Experimental convergence in two mouse models** Chronic ImP exposure is examined in 5XFAD and PS19P301S mice, with littermate controls and blinded image analysis. Amyloid, astroglial, proteomic, and tau-related outcomes provide convergent preclinical evidence.
  - Dimension: methodological rigour
  - Location: Results, Fig. 5; Methods, “Study design”
- **Specific mechanistic follow-up of tau signaling** Phosphoproteomic enrichment nominates GSK3β, and primary-neuron experiments show reversal of ImP-associated tau phosphorylation with a GSK3β inhibitor. The experiment provides a concrete mechanism for further testing.
  - Dimension: contribution
  - Location: Results, Fig. 6f–j

## Limitations

- **Microbiome findings lack multiplicity control** The CSF and plasma biomarker panels use FDR-unadjusted P values across numerous MAG–outcome comparisons. Appropriate correction could materially reduce the set of supported urdA-positive taxon associations.
  - Dimension: methodological rigour
  - Location: Results, Fig. 3b and 3d
- **Single variant cannot establish causality** The Mendelian-randomization estimate uses one locus with several cis-eQTL targets, preventing meaningful assessment of horizontal pleiotropy. The human causal interpretation therefore exceeds what Fig. 4 identifies.
  - Dimension: methodological rigour
  - Location: Results, Fig. 4; Discussion, paragraphs 1–2
- **Longitudinal and protocol reporting are unstable** ImP groups are defined using pooled or average measurements rather than a clearly prior exposure, and projected crossover ages carry strong interpretation. Treatment timing and wound-healing time points also differ between Results and Methods.
  - Dimension: reporting
  - Location: Results, Figs. 1f, 2b, and 6c–d; Methods, “Animal husbandry,” “Cell culture assays,” and “Statistical analysis”

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "Mendelian randomization analyses with a limited number of instrumental variables did provide evidence that the relationship between ImP and cognitive traits in humans was causal." (Discussion, limitations) vs "a 1 standard-deviation increase in genetically predicted normalized ImP levels was associated with greater risk of AD (OR = 1.16; 95% CI 1.05–1.29; P = 3.0 × 10-3)" (Results, Genetically increased plasma ImP levels are associated with increased AD risk). The reported Mendelian randomization outcome is AD risk, whereas the Discussion attributes its causal evidence to cognitive traits, for which no Mendelian randomization result is presented. → Not supported by the paper's own data
- **Reporting and transparency:** Noted. The longitudinal grouping rule, 5XFAD treatment start age, and endothelial wound-healing observation times are reported differently across sections; their effects on the numerical results cannot be determined.
  - Ethics approval: declared · Data availability: declared
- **Reference integrity:** Clean
  - 74 references in manuscript
  - 73 of 73 checkable references found in an index
  - 1 have no canonical index record — counted, but not index-checkable
  - 3 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
